GE Healthcare Limited — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

4 Recruiting

4 Completed trials

6 Countries active

5 Unique IMPs

100% Results reported

Phase II/III

Phase I/II

Phase III/IV

Phase IV

Phase I

Phase I (Other)

Other

Phase II/III: 1 Phase I/II: 2 Phase III/IV: 1 Phase IV: 1 Phase I: 1 Phase I (Other): 2 Other: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 1 Hormone receptor positive breast cancer 1 Hormone receptor negative HER2 positive breast cancer 1 HER2 negative breast cancer 1 Scan with contrast 1 Breast cancer metastatic 1 Oestrogen receptor gene overexpression 1

Top IMPs

(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 GADOBUTROL 1 REGADENOSON 1

All trials

9 total

Phase 4 Paediatric Study to Evaluate Sonazoid™ Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging. Pending

2023-505569-95-00 Phase III/IV 2 countries
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients with Colorectal, Gastric, … Recruiting

2024-519384-18-00 Phase II/III 2 countries (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
A Phase 1 Study to Assess Radiation Biodistribution, Dosimetry, Pharmacokinetics and Safety of GEH300079 (68Ga) Injection and Determine the … Recruiting

2025-522541-21-00 Phase I (Other) 1 country
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and … Recruiting

2024-515218-42-00 Phase I 1 country
A clinical trial to be conducted in many hospitals and in different countries with the medicinal substance Regadenoson to be used in a type … Recruiting

2024-515244-22-00 Phase I/II 3 countries GADOBUTROL; REGADENOSON
A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patie… Ended

2023-507720-23-00 Phase I/II 1 country
A Study to Assess the Effectiveness of Different Doses of GEH200486 Injection for Contrast-enhanced Head and Neck MRI in Healthy Volunteers Ended

2024-516751-41-00 1 country
Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after… Ended

2024-517400-11-00 Phase IV 1 country
A Phase 1, Randomized, Double-Blind, Placebo and Positive-Controlled Crossover Study to Evaluate the Effect of Clinical and Supraclinical Do… Ended

2023-504310-30-00 Phase I (Other) 1 country

Showing 1–9 of 9 trials

← All sponsors A–Z